Asthma is a chronic inflammatory lung condition characterised by variable respiratory symptoms (wheeze, shortness of breath, cough, and chest tightness) and variable expiratory airflow limitation, usually associated with airway inflammation. It affects 1-in-11 people in the UK and is the cause of over 75 000 hospital admissions per year. Given its prevalence, and the fact that patients are mainly cared for in the community, this article aims to highlight the need for a thorough annual asthma review and what that review entails. When carried out effectively, an asthma review will improve quality of life for those living with the condition, reduce their likelihood of hospital admission and reduce the cost to the NHS as a whole.
GambleJStevensonMMcCleanE, et al.(2009) The prevalence of nonadherence in difficult asthma. American Journal of Respiratory and Critical Care Medicine180(9): 817–822. DOI: 10.1164/rccm.200902-0166OC.
4.
GarrettJFenwickJMTaylorG, et al.(1994) Peak expiratory flow meters (PEFMs)--who uses them and how and does education affect the pattern of utilisation?Australian and New Zealand Journal of Medicine24(5): 521–529. DOI: 10.1111/j.1445-5994.1994.tb01752.x.
5.
JuniperEFBousquetJAbetzL, et al.(2006) Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respiratory Medicine100(4): 616–621. DOI: 10.1016/j.rmed.2005.08.012.
6.
JuniperEFGuyattGHFerriePJ, et al.(1993) Measuring quality of life in asthma. The American Review of Respiratory Disease147(4): 832–838. DOI: 10.1164/ajrccm/147.4.832.
MukherjeeMStoddartAGuptaRP, et al.(2016) The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: Analyses of standalone and linked national databases. BMC Medicine14(1): 1–5. DOI: 10.1186/s12916-016-0657-8.
9.
NathanRASorknessCAKosinskiM, et al.(2004) Development of the asthma control test: A survey for assessing asthma control. The Journal of Allergy and Clinical Immunology113(1): 59–65. DOI: 10.1016/j.jaci.2003.09.008.
10.
NICE (2017) Asthma: Diagnosis, monitoring and chronic asthma management. Available at: www.nice.org.uk/guidance/ng80 (accessed 24 June 2021).
NwaruBIEkströmMHasvoldP, et al.(2020) Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: A nationwide cohort study of the global SABINA programme. European Respiratory Journal55(4): 1901872DOI:10.1183/13993003.01872-2019.
13.
PearsonMGBucknallCE (1999) Measuring Clinical Outcome in Asthma: A Patient-Focused Approach, London: Royal College of Physicians of London.
14.
PinnockHParkeHLPanagiotiM, et al.(2017) Systematic meta-review of supported self-management for asthma: A healthcare perspective. BMC Medicine15(1): 64DOI: 10.1186/s12916-017-0823-7.
RCP (2014) Why Asthma Still Kills: The National Review of Asthma Deaths (NRAD). Confidential enquiry report. London: Royal College of Physicians. Available at: www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills (accessed 21 January 2021).
17.
RyanDMurphyAStallbergB, et al.(2013) ‘SIMPLES’: A structured primary care approach to adults with difficult asthma. Primary Care Respiratory Journal22: 365–373. DOI: 10.4104/pcrj.2013.00075.
StanfordRHShahMBD'SouzaAO, et al.(2012) Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Annals of Allergy, Asthma & Immunology: Official publication of the American College of Allergy, Asthma, & Immunology109(6): 403–407. DOI: 10.1016/j.anai.2012.08.014.
